Joint Meeting of the Pediatric Advisory Committee and the Pediatric Ethics Subcommittee; Notice of Meeting; Establishment of a Public Docket; Request for Comments, 19057-19058 [2017-08299]
Download as PDF
19057
Federal Register / Vol. 82, No. 78 / Tuesday, April 25, 2017 / Notices
estimated burden. This burden estimate
assumes that there are approximately
2,520 IRBs, that each IRB meets on an
average of 14.6 times annually, and that
approximately 100 hours of person-time
per meeting are required to meet the
requirements of the regulation.
In the Federal Register of November
1, 2016 (81 FR 75826), we published a
60-day notice requesting public
comment on the proposed extension of
this collection of information. No
comments were received in response to
the notice.
FDA estimates the burden of this
collection as follows:
TABLE 1—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1
21 CFR part 56; subpart D; records and reports
Number of
recordkeepers
Number of
records per
recordkeeper
Total annual
records
Average
burden per
recordkeeping
Total hours
56.115 ..................................................................................
2,520
14.6
36,792
100
3,679,200
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: April 19, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–08327 Filed 4–24–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA 2017–N–1780]
Joint Meeting of the Pediatric Advisory
Committee and the Pediatric Ethics
Subcommittee; Notice of Meeting;
Establishment of a Public Docket;
Request for Comments
AGENCY:
Food and Drug Administration,
HHS.
Notice of meeting;
establishment of a public docket,
request for comments.
ACTION:
The Food and Drug
Administration (FDA or Agency)
announces a forthcoming public
advisory committee meeting of the
Pediatric Advisory Committee (PAC)
and the Pediatric Ethics Subcommittee
(PES). The general function of the
committees is to provide advice and
make recommendations to the Agency
on pediatric ethical issues. The meeting
will be open to the public. FDA is
establishing a docket for public
comments on this document.
DATES: The meeting will be held on May
18, 2017, from 8:30 a.m. to 5:30 p.m.
The docket number is FDA 2017–N–
1780. The docket will close on May 19,
2017. Comments received on or before
May 5, 2017 will be provided to the
committee. Comments received after the
date will be taken into consideration by
the Agency.
ADDRESSES: FDA White Oak Campus,
10903 New Hampshire Ave., Building
31 Conference Center, the Great Room
(Rm. 1503, section A), Silver Spring,
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:42 Apr 24, 2017
Jkt 241001
MD 20993–0002. For those unable to
attend in person, the meeting will also
be webcast. The link for the webcast is
available at https://
collaboration.fda.gov/pacm051817.
Answers to commonly asked questions
including information regarding special
accommodations due to a disability,
visitor parking, and transportation may
be accessed at https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm408555.htm.
You may submit your comments as
follows:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to make available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submission as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA 2017–
N–1780 for the ‘‘Joint Meeting of the
Pediatric Advisory Committee and the
Pediatric Ethics Subcommittee; Notice
of Meeting; Establishment of a Public
Docket; Request for Comments.’’
Received comments will be placed in
the docket and, except for those
submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Division of Dockets Management
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
comments and you must identify this
E:\FR\FM\25APN1.SGM
25APN1
asabaliauskas on DSK3SPTVN1PROD with NOTICES
19058
Federal Register / Vol. 82, No. 78 / Tuesday, April 25, 2017 / Notices
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
accordance with 21 CFR 10.20 and other
applicable disclosure law. For more
information about FDA’s posting of
comments to public dockets, see 80 FR
56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Marieann Brill, Office of the
Commissioner, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 32, Rm. 5154, Silver Spring,
MD 20993, 240–402–3838, email:
marieann.brill@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s Web site at https://
www.fda.gov/AdvisoryCommittees/
default.htm. Scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before coming to the
meeting.
SUPPLEMENTARY INFORMATION:
Agenda: On May 18, 2017, the PAC
and the PES will meet to discuss a
referral by an Institutional Review
Board (IRB) of a clinical investigation
that involves children and FDA
regulated products. The clinical
investigation is entitled ‘‘A DoubleBlind, Placebo-Controlled, Multi-Center
Study with an Open-Label Extension to
Evaluate the Efficacy and Safety of SRP–
4045 and SRP–4053 in Patients with
Duchenne Muscular Dystrophy.’’
Comments about the upcoming joint
meeting should be submitted to Docket
No. FDA 2017–N–1780.
After presentation of an overview of
the IRB referral process under 21 CFR
50.54, an overview of the protocol and
the issues raised by the IRB referral,
other relevant presentations about the
request to modify the protocol, and a
VerDate Sep<11>2014
17:42 Apr 24, 2017
Jkt 241001
summary of the public comments
received concerning whether the
protocol should proceed as modified,
the committee will discuss the protocol
modification and develop a
recommendation regarding whether the
protocol should proceed as modified.
The committee’s recommendation will
then be presented to the Commissioner
of Food and Drugs.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material will
be available at: https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before May 11, 2017. Oral
presentations from the public will be
scheduled on May 18, 2017 between
approximately 11 a.m. and 12:30 p.m.
Those individuals interested in making
formal oral presentations should notify
the contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before May 3, 2017. Time allotted for
each presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by May 4, 2017.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
For press inquiries, please contact the
Office of Media Affairs at fdaoma@
fda.hhs.gov or 301–796–4540.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact Marieann Brill
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: April 19, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–08299 Filed 4–24–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2005–N–0464 (Formerly
Docket No. 2005N–0403)]
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Establishment Registration of
Producers of Drugs and Listing of
Drugs in Commercial Distribution and
Blood Establishment Registration and
Product Listing
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that two collections of information:
‘‘Establishment Registration of
Producers of Drugs and Listing of Drugs
in Commercial Distribution’’ and
‘‘Blood Establishment Registration and
Product Listing’’ have been approved by
the Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995.
FOR FURTHER INFORMATION CONTACT:
JonnaLynn Capezzuto, Office of
Operations, Food and Drug
Administration, Three White Flint
North 10A–12M, 11601 Landsdown St.,
North Bethesda, MD 20852, 301–796–
3794.
SUMMARY:
On
December 16, 2016, the Agency
submitted proposed collections of
information entitled ‘‘Establishment
Registration of Producers of Drugs and
Listing of Drugs in Commercial
Distribution’’ and ‘‘Blood Establishment
Registration and Product Listing’’ to
SUPPLEMENTARY INFORMATION:
E:\FR\FM\25APN1.SGM
25APN1
Agencies
[Federal Register Volume 82, Number 78 (Tuesday, April 25, 2017)]
[Notices]
[Pages 19057-19058]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-08299]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA 2017-N-1780]
Joint Meeting of the Pediatric Advisory Committee and the
Pediatric Ethics Subcommittee; Notice of Meeting; Establishment of a
Public Docket; Request for Comments
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of meeting; establishment of a public docket, request
for comments.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) announces a
forthcoming public advisory committee meeting of the Pediatric Advisory
Committee (PAC) and the Pediatric Ethics Subcommittee (PES). The
general function of the committees is to provide advice and make
recommendations to the Agency on pediatric ethical issues. The meeting
will be open to the public. FDA is establishing a docket for public
comments on this document.
DATES: The meeting will be held on May 18, 2017, from 8:30 a.m. to 5:30
p.m. The docket number is FDA 2017-N-1780. The docket will close on May
19, 2017. Comments received on or before May 5, 2017 will be provided
to the committee. Comments received after the date will be taken into
consideration by the Agency.
ADDRESSES: FDA White Oak Campus, 10903 New Hampshire Ave., Building 31
Conference Center, the Great Room (Rm. 1503, section A), Silver Spring,
MD 20993-0002. For those unable to attend in person, the meeting will
also be webcast. The link for the webcast is available at https://collaboration.fda.gov/pacm051817. Answers to commonly asked questions
including information regarding special accommodations due to a
disability, visitor parking, and transportation may be accessed at
https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm.
You may submit your comments as follows:
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to make available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submission as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Division of
Dockets Management, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA 2017-N-1780 for the ``Joint Meeting of the Pediatric Advisory
Committee and the Pediatric Ethics Subcommittee; Notice of Meeting;
Establishment of a Public Docket; Request for Comments.'' Received
comments will be placed in the docket and, except for those submitted
as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Division of Dockets Management between 9
a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Division of Dockets Management. If you do not
wish your name and contact information to be made publicly available,
you can provide this information on the cover sheet and not in the body
of your comments and you must identify this
[[Page 19058]]
information as ``confidential.'' Any information marked as
``confidential'' will not be disclosed except in accordance with 21 CFR
10.20 and other applicable disclosure law. For more information about
FDA's posting of comments to public dockets, see 80 FR 56469, September
18, 2015, or access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Division of Dockets Management, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Marieann Brill, Office of the
Commissioner, Food and Drug Administration, 10903 New Hampshire Ave.,
Bldg. 32, Rm. 5154, Silver Spring, MD 20993, 240-402-3838, email:
marieann.brill@fda.hhs.gov, or FDA Advisory Committee Information Line,
1-800-741-8138 (301-443-0572 in the Washington, DC area). A notice in
the Federal Register about last minute modifications that impact a
previously announced advisory committee meeting cannot always be
published quickly enough to provide timely notice. Therefore, you
should always check the Agency's Web site at https://www.fda.gov/AdvisoryCommittees/default.htm. Scroll down to the appropriate advisory
committee meeting link, or call the advisory committee information line
to learn about possible modifications before coming to the meeting.
SUPPLEMENTARY INFORMATION:
Agenda: On May 18, 2017, the PAC and the PES will meet to discuss a
referral by an Institutional Review Board (IRB) of a clinical
investigation that involves children and FDA regulated products. The
clinical investigation is entitled ``A Double-Blind, Placebo-
Controlled, Multi-Center Study with an Open-Label Extension to Evaluate
the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients with
Duchenne Muscular Dystrophy.'' Comments about the upcoming joint
meeting should be submitted to Docket No. FDA 2017-N-1780.
After presentation of an overview of the IRB referral process under
21 CFR 50.54, an overview of the protocol and the issues raised by the
IRB referral, other relevant presentations about the request to modify
the protocol, and a summary of the public comments received concerning
whether the protocol should proceed as modified, the committee will
discuss the protocol modification and develop a recommendation
regarding whether the protocol should proceed as modified. The
committee's recommendation will then be presented to the Commissioner
of Food and Drugs.
FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its Web site prior to the meeting, the
background material will be made publicly available at the location of
the advisory committee meeting, and the background material will be
posted on FDA's Web site after the meeting. Background material will be
available at: https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting
link.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before May
11, 2017. Oral presentations from the public will be scheduled on May
18, 2017 between approximately 11 a.m. and 12:30 p.m. Those individuals
interested in making formal oral presentations should notify the
contact person and submit a brief statement of the general nature of
the evidence or arguments they wish to present, the names and addresses
of proposed participants, and an indication of the approximate time
requested to make their presentation on or before May 3, 2017. Time
allotted for each presentation may be limited. If the number of
registrants requesting to speak is greater than can be reasonably
accommodated during the scheduled open public hearing session, FDA may
conduct a lottery to determine the speakers for the scheduled open
public hearing session. The contact person will notify interested
persons regarding their request to speak by May 4, 2017.
Persons attending FDA's advisory committee meetings are advised
that the Agency is not responsible for providing access to electrical
outlets.
For press inquiries, please contact the Office of Media Affairs at
fdaoma@fda.hhs.gov or 301-796-4540.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
disabilities. If you require accommodations due to a disability, please
contact Marieann Brill at least 7 days in advance of the meeting.
FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: April 19, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-08299 Filed 4-24-17; 8:45 am]
BILLING CODE 4164-01-P